Top 5 Drug Type | Count |
---|---|
Radionuclide Drug Conjugates (RDC) | 1 |
Hormone | 1 |
Therapeutic radiopharmaceuticals | 1 |
T-lymphocyte cell therapy | 1 |
Proteolysis-targeting chimeras (PROTAC) | 1 |
Target |
Mechanism Akt-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Inhibitors of apoptosis (IAP) protein family inhibitors [+4] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD3 stimulants [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Iopofosine I-131 ( Akt-1 ) | Non-Small Cell Lung Cancer More | Phase 2 |
Xevinapant ( IAP x XIAP x cIAP1 x cIAP1/cIAP2 ) | Lymphoma More | Phase 2 |
Anti-CD3 and anti-HER2 BiTE-expressing T cell(University of Michigan College of Engineering) ( CD3 x HER2 ) | Breast Cancer More | Phase 2 |
Somatropin(University of Michigan College of Engineering) ( GHR ) | Anterior Cruciate Ligament Injuries More | Phase 2 |
CBPD-268 ( CREBBP x EP300 x EP300/CBP ) | Prostatic Cancer More | Preclinical |